BTA injections can treat infantile esotropia

Article

Botulinum toxin type A (BTA) injections, with or without sodium hyaluronate (SH), are effective and feasible for the treatment of infantile esotropia.

Botulinum toxin type A (BTA) injections, with or without sodium hyaluronate (SH), are effective and feasible for the treatment of infantile esotropia, claims a paper in the journal Eye.

The investigation, led by Dr J. Chen, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou, China, included 47 patients with infantile esotropia who were randomly divided into two groups. Group A included 23 cases treated with bilateral injection of 2.5–3.75 U BTA combined with sodium hyaluronate (SH). In group B 24 patients were administered the BTA solution with SH. All patients did not undergo electromyography and injections were evaluated two weeks, three months and six months postoperatively.

Both groups presented with good alignment six months after injections, with group A at 30.4% and group B at 37.5%. Complicated ptosis and vertical deviation were 2.2% vs 20.8% and 2.2% vs 2.1% in groups A and B, respectively.

BTA injections with or without SH produced similar results and demonstrated effectiveness and feasibility. However, BTA injections with SH relatively decrease the frequency of complicated ptosis.

The abstract can be read here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.